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s u m m a r y
In the Netherlands, the number of notiﬁed human Q fever cases showed a steep increase over the last
three years and is not expected to disappear in the next few years. Since vaccinationmight be an option toccepted 1 November 2010
vailable online 19 November 2010
eywords:
fever
prevent Q fever cases in the general population, evidence is needed about its effectiveness. We therefore
conducted a meta-analysis to determine the evidence base for effectiveness for Q fever vaccination in
human populations. We calculated Mantel-Haenszel risk ratios and we used the following formula to
calculate the vaccines effectiveness: (1−mhRR)×100%. Although individual and the pooled estimates
showed a high effectiveness of Q fever vaccine, conclusions for the general population cannot be con-
ﬁdently drawn about vaccine effectiveness due to potential ﬂaws in the design of the studies and theaccination
ffectiveness selected group of study participants.
© 2010 Elsevier Ltd. All rights reserved.
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. Introduction
In the Netherlands, the number of notiﬁed humanQ fever cases,
aused by Coxiella burnetii, showed a steep increase over the last
hree years, with 168 versus 2357 new cases in 2007 and 2009
immunocompromised persons and thosewith pre-existing cardiac
valve- or vessel-defects [2].
Currently only one Q fever vaccine (Q-Vax, Commonwealth
Serum Laboratories Limited) is available for humans. This vaccine
is registered in Australia and is there used in the population thatespectively [1]. Despite many measures being taken to prevent
urther transmission in the Netherlands, it can be expected that Q
ever cases will occur in the next few years [1]. This is a serious
azard not only for those at high occupational risk to get the dis-
ase, but also to other vulnerable groups, such as pregnantwomen,
∗ Corresponding author. Tel.: +31 50 36 15753; fax: +31 50 36 14493.
E-mail addresses: g.gefenaite@med.umcg.nl (G. Gefenaite),
.munster@og.umcg.nl (J.M. Munster), rvhoudt@ggd.amsterdam.nl (R. van Houdt),
.hak@rug.nl (E. Hak).
264-410X/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2010.11.008has the highest occupational risk (mainly abattoir workers). Since
vaccination with Q fever vaccine might be an option to prevent
symptomatic andasymptomatic cases ofQ fever in the general pop-
ulation, evidence is needed about its effectiveness. In 2007, a paper
discussing the effectiveness of human Q fever vaccine was pub-
lished [3]. However, although this study gave a good overview of
literature, it did not aim to conduct a systematic analysis of current
evidence for Q fever vaccine effectiveness.
We therefore conducted a meta-analysis to determine the evi-
dence for the effectiveness of Q fever vaccination in humans in a
systematic way. Furthermore, as studies on the effectiveness of Q
fever vaccination were often small and probably biased, we aimed
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o assess bias by using the assessment criteria for randomized con-
rolled trials and observational studies.
. Methods
A review of literature was done by searching PubMed and the
eferences of included papers. Our search was limited to human
tudies in the English language. The search strategy was: ((Q fever
R Coxiella burnettiOR C. burnetti) AND (vaccination OR vaccine OR
mmunizedOR immunisation)). Firstwepre-screened the titles and
he abstracts; afterwards the eligibility of the studies was judged
y reading the full-text. Only the studies that used Q fever vac-
ine in human and gave information about the clinical outcome
nd reported the raw data were included in the analysis. The ﬁnal
nalysiswas performed on the effectiveness of Q-Vax (CSL Limited)
accine.
The design and possible limitations of the studieswere assessed
sing criteria for randomized control trials [4] and longitudinal
on-randomized observational studies [5]. As the main possible
imitations we considered bias because of information, selection or
onfounding, which may lead to the over- or underestimation of
he vaccine effectiveness.
The Mantel-Haenszel risk ratio (mhRR) was calculated after
ooling the raw data by using Episheet by Rothman [6,7].
accine effectiveness was calculated by the following formula:
1−mhRR)×100%.
. Results
.1. Results of the searchThe ﬁrst search resulted in more than a hundred hits. Only ﬁve
rticles met our inclusion criteria, and three extra papers were
ncluded after screening the references (Fig. 1). We had to exclude
ne paper [8] that described an interim analysis as we included theiagram.
complete study inourmeta-analysis [9]. Finally, our search resulted
in seven studies containing the raw data about the effectiveness of
the Q fever vaccine [9–15]. Four of them contained the raw data
about the effectiveness of Q-Vax (CSL Limited) [9,10,13,15].
We included three retrospective cohort studies [10,13,14], one
prospective cohort study [9], one randomized controlled trial [15]
and two experimental studies [11,12]. Except for the volunteers in
theexperimental studies, the studypopulation consistedofpersons
whoare at risk to getQ fever due to their profession,mostly abattoir
workers and laboratory staff.
The summary of the included studies can be found in Table 1.
3.2. Assessment of vaccine effectiveness
All of the studies showed a protective effect of the vaccine
against Q fever (ranged between 91 and 100%). The overall effec-
tiveness of the vaccine as calculated after pooling the raw data was
97% (95% conﬁdence interval 94–99%).
The incubation time of Q fever is around 15 days. Therefore,
thosewho developed clinical signs and symptoms of Q feverwithin
15 days after vaccination could be considered to be vaccinated
within the incubation time of a natural infection. After exclud-
ing those cases, the vaccine effectiveness increased to 99% (95%
conﬁdence interval 96–99.7%).
The effectiveness of Q-Vax (CSL Limited) vaccine was 98% (95%
conﬁdence interval 94–99%), and reached 100% after excluding the
cases that occurred within 15 days after vaccination.
3.3. Assessment of biasOne of the problems in the reviewed studies was possible bias
due to the inclusion and exclusion criteria of vaccinees and nonva-
ccinees. In six of the reviewed studies the subjects were excluded
from receiving Q fever vaccination when they had a positive anti-










Description of studies included into meta-analysis.
Ackland et al. [10] Benenson [11] Gilroy et al. [13] Marmion et al. [9] aPhilip [14] aRichard B. Hornick
[12,14]
Shapiro et al. [15]
Used Q-fever vaccine and dosage Q-Vax, CSL (3 batches of


















Experimental study RCT, double blind,
crossover
Intervention for control group – – – – – – Flu-vax .05 ml
Setting, study population 3 Australian abattoirs,
workers
USA, men volunteers 1 Australian abattoir, workers 1 Australian
abattoir, workers
Laboratory staff USA, volunteers 3 Australian
abattoirs, workers
Exclusion and inclusion criteria for
vaccinees
Exclusion: positive
serology (CF titer > =2.5) or
skin test positive (presence
of induration at 5–7 days);
with a few exceptions
None Inclusion: negative serology
(CF titer <2.5) and skin test














Exclusion and inclusion criteria for
nonvaccinees
Not given, but most likely
both, who have positive
and negative markers for
Q-fever
None None Both; but
possibility to see
the raw data with
the same inclusion









Case deﬁnition “The pattern of symptoms










Conﬁrmed case: > =4 increase
in antibody titer to phase II
antigen (AG) by CFTc or a
positive IgM titer (> =80) to
phase II AG by IFTd. Suspected




serological tests negative or
not available.
Not given Not given Not given Suspected Q fever
cases tested by CFT,
IFT
Number of cases among vaccinees 2e/2553 2/27 0/19 2e/690 0/282 2/83 0/98
Number of cases among
nonvaccinees
55/1365 8/10 7/68 7/61 2/37 5/6 7/102
Effectiveness (RR, CI 95%) 98% (92%-99%) 91% (64%-98%) 100% 97% (88%-99%) 100% 97% (88%-99%) 100%
Effectivenessb 100% – – 100% – – –
Limitations 1. Vague deﬁnition of cases 1. Vague deﬁnition of
cases
1. No description of baseline









































3. No randomization or
allocation procedures
described













a These studies were described in review papers by Fiset [12] and Ormsbee [14].
b After excluding those who got ill within 15 days after receiving Q-fever vaccine.
c Complement ﬁxation test.
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owever there were exceptions and in some cases the thresholds
f serological and/or skin tests were not given [10–12,14]. In three
tudies the inclusion and exclusion criteria for nonvaccinees were
ot given or it was different from the criteria used for vaccinees
10,11,13]. The inclusion of skin- and/or seropositive nonvaccinees
ight have led to underestimation of vaccine effectiveness as per-
ons with positive markers are thought not to be at risk for Q fever
nfection.
Furthermore, vague or even absent case deﬁnition might have
ed to both under- and overestimation of vaccine effectiveness due
o lack of objective assessment. Only in one of the reviewed stud-
es Q fever case deﬁnition was properly described and included
oth a list of clinical symptoms and the cut-off values for serolog-
cal markers [13]. Three studies also used serological markers to
onﬁrm suspected Q fever cases [10,11,15]; however the detailed
escription, including the list of symptoms and the cut-off points of
erological markers was missing. A couple of studies did not pro-
ide any case deﬁnition. Only one of the reviewed studies was a
linded study [13].
The absence of the description of the baseline characteristics of
oth vaccinees and nonvaccinees might have led to bias as well.
he description of baseline characteristics, such as gender or age,
f vaccinees and nonvaccinees was poor or absent in six studies
10–15]. For example, according to the National Q fever manage-
ent program in Australia, the incidence and vaccination against Q
ever is higher in males than in females [16]. There is already some
vidence from animal studies that females are less susceptible to
fever infection than males due to female hormones [17]. Such
ifferences in the distribution of gender between vaccinees and
onvaccinees at baseline therefore might lead to bias. Only one of
he reviewed studies provided a sufﬁcient description of baseline
haracteristics [9].
. Discussion
Individual studies showed that the effectiveness of the vaccine
gainst Q fever is very high, without exceptions [9–15]. The same
igh vaccine effectiveness was found after pooling the raw data.
ven when cases that occurred within 15 days after vaccination
ere included, the vaccine effectiveness was very high. However,
he designs of the included studies had some potential ﬂaws.
Different inclusion and exclusion criteria for vaccines and non-
accinees, inclusion of seropositive nonvaccinees, vague or absent
fever case deﬁnition, and differences in baseline characteristics
f vaccinees and nonvaccinees might have led to biased results of
fever vaccine effectiveness.
Another major problem was the selected study sample: there
ere two studies performed on volunteers, four of the studies
ocused on abattoir workers and one study focused on laboratory
taff. Although information about the demographic characteristics
as limited, the study samplewas relatively young. At least in three
f the reviewedstudies themeanagewasaround30years [9,10,13].
urthermore, the authors of the reviewed studies did not give infor-
ation about the health status of the study participants. Still, as the
tudy subjects were abattoir workers, laboratory staff and volun-
eers, it seems likely that they were relatively healthy. This creates
roblems to generalize the results in different populations. Addi-
ionally, it is unclear for how long the vaccine is protective against
fever, and whether this protection is the result of vaccination in
ombination with a constant exposure to Coxiella burnetii. It was
hown that the number of Q fever cases decreased with longer




In all, the vaccine effectiveness in groups with a high risk for Q
fever seems to be very high.
However, due to the selected study population and the absence
of a proper description of the studied samples and study pro-
cedures, it is not possible to generalize our results and draw
conclusion about the effectiveness of Q fever vaccine in the general
population or in speciﬁc groups of patients. One of the important
goals for the future should be decreasingQ fever incidence and pre-
vention of related complications in personswho are not at constant
exposure, but might bemore vulnerable, such as pregnant women,
immunocompromised persons or those with pre-existing cardiac
valve- or vessel-defects.
It seems likely that the vaccine against Q fever might decrease
the incidence of Q fever in these speciﬁc groups and in the gen-
eral population as well. However more blinded, randomized and
unbiased research about its effectiveness is needed.
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